Endocrine Abstracts

In type 2 diabetes (T2DM), cardiomiopathy is characterized by an impairment of diastolic performance resulting in ventricular hypertrophy and dilatation. Heart remodelling leads to an increase in its angle of torsion, measurable by innovative cine-magnetic resonance imaging (MRI). To evaluate the impact of phosphodiesterase 5 inhibitors (PDE5i) on cardiovascular performance in T2DM, we designed a randomized, placebo-controlled, double blind (subject/outcome assessor) study on ...

Background: Cyclic GMP-phosphodiesterase type 5(PDE5) inhibition was shown to counteract maladaptive cardiac changes triggered by diabetes in some, but not all studies.Objective: To assess sex differences in cardiac remodeling after PDE5 inhibition in patients with diabetic cardiomyopathy.Methods: 20-week, double-blind, randomized, placebo-controlled trial (NCT01803828). 220 men and women (45-80 years) with long-duration (>3 ye...